🔥 Find me at MedicalDevicesGroup.net 🔥
4 min reading time
Nersi Nazari, MDTX keynote speaker and CEO of VitalConnect, bet the fate of his company on the widespread adoption of continuous patient monitoring.
Sounds like a reasonable bet to me.
In his 40-minute keynote at https://medgroup.biz/Nazari (replay, slides, and transcript available), Nersi said patients and consumers are accepting the technology and clinical evidence supports its efficacy.
Continuous monitoring (CM) of vital signs is not new. In critical care, life depends on it.
So how to make CM portable, inexpensive, and effective?
Nersi: “Early warning signs can be extremely useful for saving lives and expenses.”
In the hospital, Nersi says, if you have a solution that helps in any way with sepsis, you’ll get their immediate attention. CM may be that solution – versus spot checks every 4 to 8 hours.
“Sepsis is huge in terms of the damage it does to patients, to costs, and to the healthcare system. This is one of those conditions that early detection is extremely important.”
It was an excellent talk with a solid Q&A session afterward: https://medgroup.biz/Nazari.
He also covered results from a 100-patient study, what Mercy Hospital is doing in St. Louis, and told us how CM that may have saved a life.
So if you have any interest in medtech that’s riding all the major themes – miniaturization, the Internet of Things, artificial intelligence – check out the talk. It will be worth your while.
Recommendations for our October 2018 keynote?
A little crowdsourcing here: Who should be the next keynote for MDTX, the Medical Device Technology Exchange, in October?
https://medgroup.biz/MDTX • October 2-4, 2018 • Del Mar Fairgrounds (Northern San Diego)
Make it a great week.
Joe Hage 🍨
When released, the following days can make or break a patient’s complete recovery. And with time in hospital beds so expensive, earlier releases let patients recover in the comfort of their homes.
For every person that has a legitimate “early warning sign” that might save lives and expenses, how many other people will have the same reading that is not an early warning sign of anything, but just an anomalous reading? Or even a normal reading, for that person?
Gabriel Adusei, MSc, PhD
I’ve learned that regular people/customers/consumers can make these technologies important. It can be more than just at-home monitoring too. People now have the ability to leapfrog, to the point where my anesthesiology used my (personal) device during my knee surgery! It was that or nothing, since the lab only draws blood before surgery and a couple of hours post-surgery.
The power of innovation is closer to home than you may think. It might actually be in your hands!
Marked as spam